Send me real-time posts from this site at my email

Trading List: Jan. 26 - Updates & Analyst Actions - AUPH, TDOC

Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'.

Aurinia Pharmaceuticals price target raised to $28 from $20 at RBC Capital

RBC Capital analyst Douglas Miehm raised the firm's price target on Aurinia Pharmaceuticals to $28 from $20 and keeps an Outperform rating on the shares. The company's sole product, voclosporin, is now FDA-approved for the treatment of active lupus nephritis in adults, the analyst tells investors in a research note, adding that its product label overall was in line with his expectations and its average pricing guidance was above his prior forecasts. Based on the robust Phase III data, a "sizeable" cash position, and an experienced commercialization team, Aurinia is positioned to gain market share in an "underpenetrated therapeutic area", Miehm states.

Aurinia Pharmaceuticals price target raised to $34 from $27 at Cantor Fitzgerald

Cantor Fitzgerald analyst Alethia Young raised the firm's price target on Aurinia Pharmaceuticals to $34 from $27 and keeps an Overweight rating on the shares following the FDA approval of Lupkynis, Aurinia's first commercial asset. The analyst thinks the label represents the best-case scenario and supports broad use in a large, active lupus nephritis population. Young is now modeling a probability-adjusted intellectual property beyond 2028, and thinks the dosing in the label will be a key part of defending their IP longer term.

Our Take:  After some time for this stock's price to stabilize it becomes a longer term biotech growth pick. Selling puts for better entry is a good idea. Selling covered calls for some extra cash is also a good idea here.
$AUPH, Aurinia Pharmaceuticals Inc / H1

Teladoc price target raised to $330 from $260 at BTIG

BTIG analyst David Larsen raised the firm's price target on Teladoc ($TDOC) to $330 from $260 and keeps a Buy rating on the shares. The analyst notes that the stock's recent strength is driven by several factors, including the indication made by UnitedHealth ($UNH) last week that it would work with multiple tele-health vendors, the recent spike in COVID cases driving the need for tele-health options, and the commentary by UnitedHealth about the durability of tele-health beyond the pandemic.

Our Take:  Teladoc continues to be a solid healthcare growth story.

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.


Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue